checkAd
Aerie PharmaceuticalsAktie
 
Mehr Daten anzeigen
Aerie Pharmaceuticals to Participate in the 20th Annual Needham Virtual Healthcare Conference

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases …

Wertpapier:
Aerie Pharmaceuticals Announces Publication of Peer-Reviewed Paper Evaluating the Treatment Effect of Netarsudil on Outflow Function in Steroid-Induced Glaucoma

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases …

Wertpapier:

Nachrichten

ZeitTitel
11.03.21
Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit Dry Eye Innovation Showcase
11.03.21
Aerie Pharmaceuticals to Participate in the Oppenheimer 31st Annual Virtual Healthcare Conference
25.02.21
Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
22.02.21
Aerie Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
18.02.21
Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Thursday, February 25, 2021
11.01.21
Aerie Pharmaceuticals Receives European Commission Approval for Roclanda (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%
13.11.20
Aerie Pharmaceuticals Receives Positive CHMP Opinion for Roclanda in the European Union
10.11.20
Aerie Pharmaceuticals to Participate in the Stifel 2020 Virtual Healthcare Conference
05.11.20
Aerie Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update
29.10.20
Aerie Pharmaceuticals Initiates Phase 2b Clinical Trial of AR-15512 (TRPM8 Agonist) Ophthalmic Solution for the Treatment of Patients with Dry Eye Disease
28.10.20
Santen and Aerie Conclude Exclusive License Agreement for Rhopressa and Rocklatan in Japan and Several Other Asian Countries
27.10.20
Aerie Pharmaceuticals to Announce Third Quarter 2020 Financial Results and Host Conference Call on Thursday, November 5, 2020
29.09.20
Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for AR-15512 (TRPM8 Agonist) Eye Drop for Dry Eye Disease
24.09.20
Aerie Pharmaceuticals Announces Successful Interim 90-Day Topline Data From Its Six-Month Mercury 3 Clinical Trial in Europe
15.09.20
Aerie Pharmaceuticals Announces U.S. Food and Drug Administration Approval of its Athlone, Ireland Facility for Production of Rhopressa (netarsudil ophthalmic solution) 0.02%
Diskussionen

Aerie Pharmaceuticals Forum

Die wichtigsten Links der Community
Börsenforum - der komplette Überblick
Alle Foren von Anfänger bis Zertifikate
Forum-Suche

Diskussionen

Was halten Sie von den neusten Entwicklungen zu Aerie Pharmaceuticals?


Meistdiskutierte Aktien (24h)

WertpapierBeiträge
DAX
438
Neptune Digital Assets
194
Upco International
164
Tesla
147
AMC Entertainment Holdings Registered (A)
142
NanoRepro
141
BioNTech
126
Paion
124
Coinbase Global Registered (A)
121
Lyxor ETF MSCI World D €
92